cladribine (CRD1) / EMD Serono - LARVOL DELTA

Merck KGaA...has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational cladribine capsules to treat generalized Myasthenia Gravis (gMG), a rare and debilitating autoimmune neuromuscular disorder. (Indian Pharma Post) - "Patient insights have guided study protocols, recruitment materials, and potential product packaging, ensuring the upcoming MyClad Phase 3 trial addresses real-world patient needs."

Fast track • Myasthenia Gravis

EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis (Businesswire) - "EMD Serono...announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG)....To shape the MyClad trial and ensure it meets the needs of patients, EMD Serono developed a patient council and collaborates with more than 20 MG patient advocacy groups around the world."

Commercial • Fast track • Myasthenia Gravis

AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More” (Cancer Therapy Advisor) - "'This study is important given that it is showing a new combination of upfront intensive chemotherapy with inclusion of venetoclax with encouraging response rates and tolerability,' said Hetty Carraway...who was not involved in this study."

Media quote

Hair Cell Leukemia: Single Center Experience (EHOK 2021) - "HCL treatment response rates after the use of purine analogs as first-line therapy are significant. degree increased. Splenectomy can be evaluated in relapsed or refractory disease. In relapsed cases Adding Rituximab to Cladribine increased complete response rates. BRAFV600E mutation all relapses Vemurafenib treatment should be evaluated in patients and in positive cases, Vemurafenib treatment is among the options. should be evaluated. The most common side effect is infection due to cytopenia. In terms of treatment-related malignancy patients should be carefully examined and the findings should not be ignored."

Clinical